Wuhan Keqian Biology Co Ltd (SHG:688526) — Market Cap & Net Worth
Market Cap & Net Worth: Wuhan Keqian Biology Co Ltd (688526)
Wuhan Keqian Biology Co Ltd (SHG:688526) has a market capitalization of $849.20 Million (CN¥5.80 Billion) as of September 24, 2026. Listed on the SHG stock exchange, this China-based company holds position #9765 globally and #2550 in its home market, demonstrating a 0.08% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Wuhan Keqian Biology Co Ltd's stock price CN¥12.45 by its total outstanding shares 466128056 (466.13 Million). Also see Wuhan Keqian Biology Co Ltd total assets for a full breakdown of the balance sheet.
Wuhan Keqian Biology Co Ltd Market Cap History: 2020 to 2026
Wuhan Keqian Biology Co Ltd's market capitalization history from 2020 to 2026. Data shows change from $2.71 Billion to $849.20 Million (-13.68% CAGR). Also see Wuhan Keqian Biology Co Ltd (688526) cash flow conversion for how efficiently the company converts equity into cash flow.
Wuhan Keqian Biology Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Wuhan Keqian Biology Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Wuhan Keqian Biology Co Ltd share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
1.03x
Wuhan Keqian Biology Co Ltd's market cap is 1.03 times its annual revenue
Latest Price to Earnings (P/E) Ratio
2.55x
Wuhan Keqian Biology Co Ltd's market cap is 2.55 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $2.71 Billion | $843.23 Million | $447.80 Million | 3.21x | 6.04x |
| 2021 | $1.80 Billion | $1.10 Billion | $570.74 Million | 1.64x | 3.16x |
| 2022 | $1.48 Billion | $1.00 Billion | $409.52 Million | 1.48x | 3.62x |
| 2023 | $1.36 Billion | $1.06 Billion | $395.93 Million | 1.28x | 3.43x |
| 2024 | $974.71 Million | $941.92 Million | $382.35 Million | 1.03x | 2.55x |
Competitor Companies of 688526 by Market Capitalization
Companies near Wuhan Keqian Biology Co Ltd in the global market cap rankings as of September 24, 2026. Review tangible net worth ratio of Wuhan Keqian Biology Co Ltd to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Wuhan Keqian Biology Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.53 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #334 globally with a market cap of $80.46 Billion USD.
- CSL Ltd (AU:CSL): Ranked #451 globally with a market cap of $62.04 Billion USD ( AU$87.68 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #510 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.53 Billion | $514.99 |
| #334 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $80.46 Billion | $803.90 |
| #451 | CSL Ltd | AU:CSL | $62.04 Billion | AU$180.72 |
| #510 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $182.56 |
Wuhan Keqian Biology Co Ltd Historical Marketcap From 2020 to 2026
Between 2020 and today, Wuhan Keqian Biology Co Ltd's market cap moved from $2.71 Billion to $ 849.20 Million, with a yearly change of -13.68%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥849.20 Million | -18.41% |
| 2025 | CN¥1.04 Billion | +6.79% |
| 2024 | CN¥974.71 Million | -28.29% |
| 2023 | CN¥1.36 Billion | -8.25% |
| 2022 | CN¥1.48 Billion | -17.92% |
| 2021 | CN¥1.80 Billion | -33.30% |
| 2020 | CN¥2.71 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 23rd, 2026 the market cap of Wuhan Keqian Biology Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $849.20 Million USD |
| MoneyControl | $849.20 Million USD |
| MarketWatch | $849.20 Million USD |
| marketcap.company | $849.20 Million USD |
| Reuters | $849.20 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Wuhan Keqian Biology Co Ltd
Wuhan Keqian Biology Co.,Ltd focuses on the research and development, production, sales, and animal epidemic prevention technical services of veterinary biological products in China. The company offers vaccines for pigs, poultry, and pets, as well as diagnostic reagents. Wuhan Keqian Biology Co.,Ltd was founded in 2001 and is based in Wuhan, China.